Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03959800 · ClinicalTrials.gov registry record
Molecular Basis of Pediatric Liver Cancer
A clinical trial of Hepatocellular Carcinoma and Hepatoblastoma, sponsored by University of Pittsburgh.
- Recruiting
- Registry status
- 1,600
- Enrollment target
- 1
- Study location
NCT03959800: Recruiting study of Hepatocellular Carcinoma and Hepatoblastoma, sponsored by University of Pittsburgh.
NCT03959800 is a study of Hepatocellular Carcinoma and Hepatoblastoma that is actively recruiting participants, run by University of Pittsburgh. The registered enrollment target is 1,600 participants, above the 246-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (550% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03959800, a study of Hepatocellular Carcinoma and Hepatoblastoma, is actively recruiting participants, sponsored by University of Pittsburgh.
- RECRUITING
- Registry status
- 1,600 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this retrospective and prospective project is to understand the molecular and genetic basis of liver cancer of childhood. Understanding the molecular and genetic bases of liver cancers can offer a better classification based on tumor biology, mechanisms and predisposition.
Primary Outcome
DNA sequence variants
Conditions Studied
Study Locations (1)
Pennsylvania
- UPMC Children's Hospital of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,600 participants |
| Start Date | 2015-06-22 |
| Est. Completion | 2029-06-30 |
What NCT03959800 shows while recruiting
NCT03959800 is an observational study that tracks outcomes without assigning an intervention. Its 1,600 participants enrollment target places it among the larger protocols in the corpus, above the 246-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (550% higher).
The record links to 6 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT03959800 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03959800 about?
NCT03959800 is a clinical study titled "Molecular Basis of Pediatric Liver Cancer". The purpose of this retrospective and prospective project is to understand the molecular and genetic basis of liver cancer of childhood. Understanding the molecular and genetic bases of liver cancers can offer a better classification based on tumor biology, mechanisms and predisposition.
What is the current status of trial NCT03959800?
This trial is currently recruiting. The enrollment target is 1,600 participants. The study started on 2015-06-22. Estimated completion is 2029-06-30.
What conditions does trial NCT03959800 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Hepatoblastoma, Childhood Liver Cancer, Liver Malignant Tumors, Embryonal Sarcoma of Liver (Disorder).
Who is sponsoring clinical trial NCT03959800?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03959800 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03959800's enrollment target sits among peer trials
1,600 4th of 145 higher than 142 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00646022 · 1,600 participants
Natural History of Familial Carcinoid Tumor
- NCT03109197 · 1,600 participants
Sudden Unexplained Death in Childhood (SUDC) Registry
- NCT03511118 · 1,600 participants
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- NCT04314401 · 1,600 participants
National Cancer Institute "Cancer Moonshot Biobank"
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI